Asset Details
Do you wish to reserve the book?
Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions
Do you wish to request the book?
Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions
2022
Overview
In the POLARIX trial, pola‐R‐CHP demonstrated improved progression‐free survival (PFS) compared to R‐CHOP in untreated intermediate‐ to high‐risk DLBCL. We surveyed practicing clinicians regarding their interpretation of POLARIX, including impressions of efficacy, safety, and cost. Of 174 respondents, most from academic centers (82%) in the United States (57%), 70% stated they would not replace R‐CHOP with pola‐R‐CHP due to insufficient PFS difference, lack of overall survival benefit, and excessive cost. Respondents not recommending pola‐R‐CHP expressed concerns about financial implications for both society and patients. We observed considerable heterogeneity in both study interpretation and plans for real‐world implementation of pola‐R‐CHP.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
